Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adavosertib and Gemcitabine in Platinum-Resistant Pancreatic Cancer
NCT05212025Phase 2Withdrawn
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of adavosertib in pancreatic adenocarcinoma (PDAC). Primary endpoint: Overall Response Rate at 2 years. Planned start Jun 2022; status: withdrawn.
02
Drugs
adavosertib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05212025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212025.